CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Ruxolitinib administrationWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D055370 Lung Injury NIH 0.32
D012128 Respiratory Distress Syndrome, Adult NIH 0.13

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of patients with COVID-19 severe pneumonia.

NCT04359290 ARDS, Human COVID Drug: Ruxolitinib administration
MeSH:Lung Injury Respiratory Distress Syndrome, Adult

Primary Outcomes

Description: To determine the efficacy of ruxolitinib measured by overall survival

Measure: Overall survival

Time: 28 days after registration into trial

Secondary Outcomes

Description: Assessment of the duration of ventilation support

Measure: Assessment of the duration of ventilation support

Time: registration unitl 90 days after registration into trial

Description: Assessment of the extent of cytokine storm reduction (IL-6, CRP, ferritin)

Measure: cytokine storm

Time: registration unitl 90 days after registration into trial

Description: To assess time on ICU

Measure: time on ICU

Time: registration unitl 90 days after registration into trial

Description: To assess toxicity and safety of ruxolitinib treatment

Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Time: registration unitl 90 days after registration into trial

Description: To assess the timeframe for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG)

Measure: time frame for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG)

Time: registration unitl 90 days after registration into trial

Description: To assess pulmonary function (time point discharge from hospital) by CT scan

Measure: pulmonary function assessed by a CT scan

Time: registration unitl 90 days after registration into trial

Description: To determine the efficacy of ruxolitinib measured by overall survival

Measure: overall survival

Time: 90 days after registration into trial


No related HPO nodes (Using clinical trials)